About Carbohydrate sulfotransferase 13
Carbohydrate sulfotransferase 13 (CHST13) is a protein
from Homo sapiens identified by UniProt accession
Q8NET6, 341 residues long.
MolForge cross-references it against 0 known binders and
28 disease associations.
Target properties
| Protein name | Carbohydrate sulfotransferase 13 |
|---|
| UniProt accession | Q8NET6 |
|---|
| Gene | CHST13 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 341 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (28)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.45
- neurodegenerative disease · score 0.36
- platelet count · score 0.31
- monocyte count · score 0.29
- pentraxin-related protein PTX3 measurement · score 0.24
- pappalysin‐1 measurement · score 0.24
- mean platelet volume · score 0.22
- lymphocyte count · score 0.04
- eosinophil percentage of leukocytes · score 0.03
- PHF-tau measurement · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8NET6-F1 | alphafold | PREDICTED | 86.52 | — |
Amino-acid sequence (341 residues)
MGRRCCRRRV LAAACLGAAL LLLCAAPRSL RPAFGNRALG SSWLGGEKRS PLQKLYDLDQ DPRSTLAKVH RQRRDLLNSA CSRHSRRQRL LQPEDLRHVL VDDAHGLLYC YVPKVACTNW KRVLLALSGQ ARGDPRAISA QEAHAPGRLP SLADFSPAEI NRRLRAYLAF LFVREPFERL ASAYRNKLAR PYSAAFQRRY GARIVQRLRP RALPDARARG HDVRFAEFLA YLLDPRTRRE EPFNEHWERA HALCHPCRLR YDVVGKFETL AEDAAFVLGL AGASDLSFPG PPRPRGAAAS RDLAARLFRD ISPFYQRRLF DLYKMDFLLF NYSAPSYLRL L
Explore Carbohydrate sulfotransferase 13 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets